HER2 activation results in concomitant triggering of the Ras-Raf-MEK-ERK pathway and PI3K-Akt-mTOR pathway, which is crucial for breast cancer cell proliferation, cancer survival, and cancer chemoresistance. Here, ERBB2 is linked to breast carcinoma.